To ensure that the HCP-LCE mutants LCE-E and LCE-D also showed more affine binding to target-positive tumor cells than the wildtype Two-in-One antibody, cellular binding experiments were performed on EGFR and PD-L1 double-positive A549 cells by flow cytometry. The gene discussed is EGFR; the disease is neoplasm.